Navigation Links
Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
Date:3/30/2011

PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The ATOMIC trial is designed to explore 12 and 24 week durations of PSI-7977. The potency, high barrier to resistance, and consistent antiviral activity across genotypes provided the data to support an interferon free dosing period in this trial, as well as enabling us to enroll multiple genotypes in this trial."  

About the Phase 2b ATOMIC Trial

This Phase 2b trial is planned to enroll approximately 300 patients with chronic HCV genotype 1 who have not been treated previously. The primary endpoint of the trial will be the safety and tolerability of PSI-7977 in combination with peginterferon and ribavirin over 12 or 24 weeks. The trial will be conducted in the U.S. Patients will be randomized (1:2:3) into the following arms:

  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 24 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks, followed by either PSI-7977 400mg QD monotherapy for 12 weeks or PSI-7977 400mg QD plus ribavirin for 12 weeks.

HCV GT1 patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. An additional 25 treatment-naïve patients w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Webcast an Investor Event From the EASL Meeting
2. Pharmasset to Present at Three Upcoming Investor Conferences
3. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
4. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
5. Pharmasset Announces Exercise of Underwriters Overallotment Option
6. Pharmasset Prices Public Offering of Common Stock
7. Pharmasset Announces Proposed Public Offering of Common Stock
8. Pharmasset Reports Positive Results from its HCV Clinical Programs
9. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
11. Pharmasset to Webcast an Investor Event from the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/27/2014)... July 27, 2014 /PRNewswire-iReach/ -- This is ... Global and Chinese Vardenafil (CAS 224785-90-4) industry. ... of Vardenafil (CAS 224785-90-4) including its classification, ... explores global and China,s top manufacturers of ... capacity, production value, cost, gross margin and ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... Modesto, CA (PRWEB) July 28, 2014 At ... an uncomfortable situation where they’re forced to contact the authorities. ... little more difficult than it initially seems. , Not every ... a vehicle get stolen, a person get mugged, or a ... little less obvious, leading onlookers to be more passive than ...
(Date:7/28/2014)... Researchers from Boston University School of Medicine (BUSM) report ... the risk of developing Alzheimer,s disease (AD). The discovery ... drug treatment options that target PLXNA4 specifically. These findings ... AD is the most frequent age-related dementia affecting 5.4 ... and older, and more than 40 percent of people ...
(Date:7/28/2014)... 28, 2014 Qualis Health, one ... management organizations, has published a complimentary, online toolkit ... engaging patients and families in infection control. ... hospitals, the toolkit provides a step-by-step roadmap for ... and their families early in a hospital stay. ...
(Date:7/28/2014)... The North America Carotenoids & Antioxidants Market ... North America with analysis and forecast of revenue. This market ... to $812.7 million by 2018, at a CAGR of 7.1% ... the North America Carotenoids & Antioxidants Market report to get ... a glimpse of the segmentation in the market, and is ...
Breaking Medicine News(10 mins):Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Researchers identify potential biomarker for AD 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... Scientists at Warwick Medical School have uncovered the molecular ... ,health checkpoint, with cells that carry unequal numbers of ... , Studying simple yeast cells, scientists now understand the ... the correct number of chromosomes. , Most ...
... State University will lead a four-year, $5 million expanded ... discover proteins, or biomarkers, to help predict cardiovascular disease ... type 2 diabetes. Nearly 26 million Americans have ... U.S. The disease is a major cause of heart ...
... , TUESDAY, Nov. 1 (HealthDay News) -- Multiple sclerosis ... aim at the abnormal behavior of a specific type of ... the cells in question -- known as "B cells" -- ... and disabling nervous system disease, commonly called MS. The ...
... high school students are considered overweight, and while a myriad ... parents can do to help curb these rates, very little ... lose weight. Research led by public health doctoral candidate ... Philadelphia report wanting to lose weight, their actions are more ...
... an eight hour shift leads to substantial cost savings and energy ... Journal of the American College of Radiology . ... the use of computers and scanning equipment. "We should ... this equipment and look for ways to reduce it, both as ...
... NYU Langone Medical Center identified for the first time that ... outer and inner layers of the brain, called "blurring", may ... development of new therapies for degenerative brain conditions, such as ... issue of the Journal of Neuroscience . ...
Cached Medicine News:Health News:Warwick scientists discover how daughter cells receive the same number of chromosomes 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 2Health News:ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment 3Health News:New Multiple Sclerosis Therapy Promising in Early Trial 2Health News:New Multiple Sclerosis Therapy Promising in Early Trial 3Health News:Study finds overweight teens want to lose weight, going about it the wrong way 2Health News:Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: